Eli Lilly and Co. has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), to study baricitinib as an arm in NIAID’s Adaptive COVID-19 Treatment Trial. The study will evaluate safety and efficacy of baricitinib as a potential treatment for hospitalized patients with COVID-19, beginning this month in the U.S. with a planned expansion to additional sites. Results are expected within the next two months. Baricitinib, an oral JAK1/JAK2 inhibitor ...